Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Celltrion

http://

Latest From Celltrion

Deal Watch: AzurRx Expands GI Pipeline With Buyout Of Partner First Wave

Stock-and-cash deal valued at $229m brings AzurRx rights to niclosamide in additional indications. Boehringer Ingelheim partners with Twist on therapeutic antibody discovery.

Deal Watch Deals

Cipla Resets Biosimilars Interest, Readies Respiratory-Focused JV

Cipla moves beyond in-licensing approach and teams up with CDMO Kemwell to develop and progress respiratory biosimilars. Commercialization of products anticipated post 2025.

Commercial Biosimilars

Xellia CEO Questions Key Ingredients Reliance Of US And Europe

In an exclusive interview with Generics Bulletin, the CEO of API and FDF manufacturer Xellia Pharmaceuticals, expresses concern over supply chain resilience of the US and the EU, as he points out the weaknesses exposed by the pandemic. The company has also announced the release of its first anti-infectives manufactured at its newly operational Cleveland site. 

Generic Drugs Manufacturing

Coronavirus Notebook: Australia OKs GSK’s Sotrovimab For COVID-19, Iran Takes SpikoGen Vaccine Into Phase III

Bavarian Nordic is testing the potential of its ABNCoV2 vaccine as a booster dose for people with previous infection or vaccination. Brazil has received requests from Pfizer/BioNTech and AstraZeneca to trial vaccines as booster doses, and has asked for more immunogenicity data on SinoVac’s CoronaVac.

Brazil Australia
See All

Company Information

  • Industry
  • Pharmaceuticals
UsernamePublicRestriction

Register